JP2016526023A - Ｓｔａｔ６阻害剤 - Google Patents

Ｓｔａｔ６阻害剤 Download PDF

Info

Publication number
JP2016526023A
JP2016526023A JP2016513077A JP2016513077A JP2016526023A JP 2016526023 A JP2016526023 A JP 2016526023A JP 2016513077 A JP2016513077 A JP 2016513077A JP 2016513077 A JP2016513077 A JP 2016513077A JP 2016526023 A JP2016526023 A JP 2016526023A
Authority
JP
Japan
Prior art keywords
compound
alkyl
hydrogen
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016513077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526023A5 (enExample
Inventor
ジョン エス． マクマレイ
ジョン エス． マクマレイ
ピジャス クマー マンダル
ピジャス クマー マンダル
ピエトロ モルラッキ
ピエトロ モルラッキ
モーガン ナイト
モーガン ナイト
デイビッド ビー． コリー
デイビッド ビー． コリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2016526023A publication Critical patent/JP2016526023A/ja
Publication of JP2016526023A5 publication Critical patent/JP2016526023A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2016513077A 2013-05-08 2014-05-08 Ｓｔａｔ６阻害剤 Withdrawn JP2016526023A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361821181P 2013-05-08 2013-05-08
US61/821,181 2013-05-08
PCT/US2014/037342 WO2014182928A2 (en) 2013-05-08 2014-05-08 Stat6 inhibitors

Publications (2)

Publication Number Publication Date
JP2016526023A true JP2016526023A (ja) 2016-09-01
JP2016526023A5 JP2016526023A5 (enExample) 2017-06-15

Family

ID=51867868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016513077A Withdrawn JP2016526023A (ja) 2013-05-08 2014-05-08 Ｓｔａｔ６阻害剤

Country Status (6)

Country Link
US (2) US9765099B2 (enExample)
EP (1) EP2994143A4 (enExample)
JP (1) JP2016526023A (enExample)
AU (1) AU2014262621B2 (enExample)
CA (1) CA2911914A1 (enExample)
WO (1) WO2014182928A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527114A (ja) * 2019-04-05 2022-05-30 カイメラ セラピューティクス， インコーポレイテッド 分解剤およびそれらの使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
KR102444211B1 (ko) * 2020-11-03 2022-09-16 이화여자대학교 산학협력단 비감염성 염증질환의 치료용 물질 스크리닝 방법
WO2024064080A1 (en) * 2022-09-19 2024-03-28 Kymera Therapeutics, Inc. Stat6 degraders and uses thereof
TW202425965A (zh) 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
WO2025103477A1 (en) * 2023-11-17 2025-05-22 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025147320A1 (en) * 2024-01-03 2025-07-10 Kymera Therapeutics, Inc. Stat6 inhibitors and uses thereof
WO2025217647A1 (en) * 2024-04-12 2025-10-16 Kymera Therapeutics, Inc. Stat6 degraders and uses thereof

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08208462A (ja) * 1994-11-24 1996-08-13 Takeda Chem Ind Ltd カテプシンｌ阻害剤
WO1997012903A1 (en) * 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
WO1997043307A1 (en) * 1996-05-16 1997-11-20 Warner-Lambert Company Compounds inhibiting the association of the pdgf receptor and phosphatidylinositol 3-kinase and their use
WO1999024442A1 (en) * 1997-11-12 1999-05-20 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
WO2001068655A2 (en) * 2000-03-10 2001-09-20 Ariad Pharmaceuticals, Inc. Caprolactam derivatives and uses thereof
WO2001083517A1 (en) * 2000-05-03 2001-11-08 Tularik Inc. Stat4 and stat6 binding dipeptide derivatives
US6426331B1 (en) * 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
JP2003513290A (ja) * 1999-10-29 2003-04-08 フアルマシア・イタリア・エツセ・ピー・アー ターゲット生体分子と相互作用するリガンドの同定のための二量子１ｈ−ｎｍｒスペクトロスコピーの使用
JP2003525862A (ja) * 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
JP2004510732A (ja) * 2000-10-06 2004-04-08 オリオン　コーポレーション 喘息治療のための組合せ粒子
US20070010428A1 (en) * 2004-09-03 2007-01-11 Mcmurray John S Inhibitors of signal transduction and activator of transcription 3
WO2007148711A1 (ja) * 2006-06-21 2007-12-27 Institute Of Medicinal Molecular Design. Inc. N-(3,4-ジ置換フェニル)サリチルアミド誘導体
JP2008506674A (ja) * 2004-07-15 2008-03-06 アストラゼネカ・アクチエボラーグ スタチンと気管支拡張剤との組み合わせ
WO2008070833A2 (en) * 2006-12-07 2008-06-12 University Of South Florida Use of sh2 stat3/stat1 peptidomimetices as anticancer drugs
JP2010174027A (ja) * 2002-06-28 2010-08-12 Astellas Pharma Inc ジアミノピリミジンカルボキサミド誘導体
WO2010118241A2 (en) * 2009-04-08 2010-10-14 Indiana University Research & Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2010118309A2 (en) * 2009-04-10 2010-10-14 Board Of Regents, The University Of Texas System Inhibitors of stat3 and uses thereof
US20110319362A1 (en) * 2008-12-08 2011-12-29 Shaomeng Wang Stat3 ligands and therapeutic uses thereof
WO2012044999A2 (en) * 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3935895A (en) 1994-11-24 1996-06-17 Takeda Chemical Industries Ltd. Alpha-ketoamide derivatives as cathepsin l inhibitor

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08208462A (ja) * 1994-11-24 1996-08-13 Takeda Chem Ind Ltd カテプシンｌ阻害剤
WO1997012903A1 (en) * 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
WO1997043307A1 (en) * 1996-05-16 1997-11-20 Warner-Lambert Company Compounds inhibiting the association of the pdgf receptor and phosphatidylinositol 3-kinase and their use
WO1999024442A1 (en) * 1997-11-12 1999-05-20 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6426331B1 (en) * 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
JP2003525862A (ja) * 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
JP2003513290A (ja) * 1999-10-29 2003-04-08 フアルマシア・イタリア・エツセ・ピー・アー ターゲット生体分子と相互作用するリガンドの同定のための二量子１ｈ−ｎｍｒスペクトロスコピーの使用
WO2001068655A2 (en) * 2000-03-10 2001-09-20 Ariad Pharmaceuticals, Inc. Caprolactam derivatives and uses thereof
WO2001083517A1 (en) * 2000-05-03 2001-11-08 Tularik Inc. Stat4 and stat6 binding dipeptide derivatives
JP2004510732A (ja) * 2000-10-06 2004-04-08 オリオン　コーポレーション 喘息治療のための組合せ粒子
JP2010174027A (ja) * 2002-06-28 2010-08-12 Astellas Pharma Inc ジアミノピリミジンカルボキサミド誘導体
JP2008506674A (ja) * 2004-07-15 2008-03-06 アストラゼネカ・アクチエボラーグ スタチンと気管支拡張剤との組み合わせ
US20070010428A1 (en) * 2004-09-03 2007-01-11 Mcmurray John S Inhibitors of signal transduction and activator of transcription 3
WO2007148711A1 (ja) * 2006-06-21 2007-12-27 Institute Of Medicinal Molecular Design. Inc. N-(3,4-ジ置換フェニル)サリチルアミド誘導体
WO2008070833A2 (en) * 2006-12-07 2008-06-12 University Of South Florida Use of sh2 stat3/stat1 peptidomimetices as anticancer drugs
US20110319362A1 (en) * 2008-12-08 2011-12-29 Shaomeng Wang Stat3 ligands and therapeutic uses thereof
WO2010118241A2 (en) * 2009-04-08 2010-10-14 Indiana University Research & Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2010118309A2 (en) * 2009-04-10 2010-10-14 Board Of Regents, The University Of Texas System Inhibitors of stat3 and uses thereof
WO2012044999A2 (en) * 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. １７, JPN6018008753, 2007, pages 654 - 656, ISSN: 0003756531 *
BIOORG. MED. CHEM. LETT., vol. ２３, JPN6018008737, 4 February 2013 (2013-02-04), pages 2225 - 2229, ISSN: 0003756522 *
BIOORG. MED. CHEM. LETT., vol. ６, JPN6018008760, 1996, pages 1209 - 1214, ISSN: 0003756534 *
CHEMMEDCHEM, vol. ３, JPN6018008755, 2008, pages 1159 - 1168, ISSN: 0003756532 *
INT. J. PEPT. RES. THER., vol. １９, JPN6018008748, March 2013 (2013-03-01), pages 3 - 12, ISSN: 0003756528 *
J. EXP. THR. ONCOL., vol. １０, JPN6018008739, 2012, pages 155 - 162, ISSN: 0003756523 *
J. MED. CHEM., vol. ４８, JPN6018008751, 2005, pages 6661 - 6670, ISSN: 0003756530 *
J. MED. CHEM., vol. ５２, JPN6018008743, 2009, pages 2429 - 2442, ISSN: 0003756525 *
J. MED. CHEM., vol. ５２, JPN6018008750, 2009, pages 6126 - 6141, ISSN: 0003756529 *
J. MED. CHEM., vol. ５４, JPN6018008745, 2011, pages 3549 - 3563, ISSN: 0003756527 *
ORG. LETT., vol. １１, JPN6018008744, 2009, pages 3394 - 3397, ISSN: 0003756526 *
PLOS ONE, vol. ７, JPN6018008741, 2012, pages 51603, ISSN: 0003756524 *
PUBCHEM [ONLINE], JPN6018008758, 2011, pages 53248592, ISSN: 0003756533 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527114A (ja) * 2019-04-05 2022-05-30 カイメラ セラピューティクス， インコーポレイテッド 分解剤およびそれらの使用

Also Published As

Publication number Publication date
US20160145279A1 (en) 2016-05-26
WO2014182928A2 (en) 2014-11-13
AU2014262621B2 (en) 2018-03-01
US9765099B2 (en) 2017-09-19
EP2994143A4 (en) 2017-02-01
WO2014182928A3 (en) 2015-01-22
EP2994143A2 (en) 2016-03-16
CA2911914A1 (en) 2014-11-13
AU2014262621A1 (en) 2015-11-26
US20180222931A1 (en) 2018-08-09
US10385080B2 (en) 2019-08-20

Similar Documents

Publication Publication Date Title
JP2016526023A (ja) Ｓｔａｔ６阻害剤
TWI587859B (zh) 用於預防及／或治療溶素體儲積症之新穎組成物
US9884863B2 (en) STAT3 inhibitor
JP6896113B2 (ja) ジアザ二環式置換イミダゾピリミジンおよび呼吸障害を治療するためのその使用
JP6999639B2 (ja) 置換ジアザヘテロ－二環式化合物およびそれらの使用
WO2019042444A1 (zh) 一类抑制并降解酪氨酸蛋白激酶alk的化合物
KR20060130515A (ko) 폐 염증 및 기관지 수축의 치료를 위한 스테로이드 및β-작용제의 공통 프로드럭으로서의 치환된 페닐포스페이트
JP5822840B2 (ja) 眼疾患処置薬
UA128160C2 (uk) Сполуки, що інгібують rip1, а також способи їх одержання та застосування
KR20220142483A (ko) 항바이러스 화합물
JP6218940B2 (ja) キニン系化合物、その光学異性体及びその製造方法と医薬用途
EA016199B1 (ru) Соединения и композиции как ингибиторы активирующей канал протеазы
WO2010126953A1 (en) Corticosteroid linked beta-agonist compounds for use in therapy
JPWO2012127885A1 (ja) テトラヒドロカルボリン誘導体
JP2022545542A (ja) ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
KR20240115978A (ko) Lpa 수용체 길항제 및 이의 용도
WO2020118564A1 (en) Novel thyromimetics
JP2024511452A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
CN114072381B (zh) 氨基硫醇类化合物作为脑神经或心脏保护剂的用途
CN114671856B (zh) 多取代的尿嘧啶衍生物及其用途
US11958869B2 (en) Ruthenium arene Schiff-base complexes and uses thereof
EP3952866B1 (en) Benzimidazole derivatives and their uses
EP4013420B1 (en) Method of blocking or ameliorating cytokine release syndrome
WO2023038815A1 (en) Irak inhibitor for treating cytokine release-related conditions associated with infection by a respiratory virus
TW201831482A (zh) 新穎雜環化合物及其預防或治療細菌感染之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190219

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190405

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200428